Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

索坦 - NMPA Drug Approval Details

Approvals/NMPA/Sunitinib Malate Capsules

Approved

化学药品

Sunitinib Malate Capsules

Pfizer Europe MA EEIG🇨🇳 National Medical Products Administration

Approval Date: Jul 29, 2022
Approval ID: b042c99bc3b6d480
Company: Pfizer Europe MA EEIG
Type: 化学药品

Approval Details

Approval Id: b042c99bc3b6d480
Approval Number: 国药准字HJ20171141
Generic Name: 苹果酸舒尼替尼胶囊
Generic Name En: Sunitinib Malate Capsules
Trade Name: 索坦
Drug Type: 化学药品
Dosage Form: 胶囊剂
Strength: 37.5mg
Reg Date: 2022-07-29
Expired Date: 2027-07-28
Company Name: Pfizer Europe MA EEIG
Production Company Name: Pfizer Italia S.R.L.
Company Detail Path: /organization/pfizer-europe-ma-eeig
Production Company Detail Path: /organization/pfizer-italia-s-r-l

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Jul 29, 2022

Approval ID

b042c99bc3b6d480

Type

化学药品

Back to NMPA Approvals